Close Menu

Wearable Sensors May Predict Early Onset of Illness, Study Says

NEW YORK (360Dx) – During routine patient visits, physicians generally measure heart rate, blood pressure, and body temperature, but these parameters may need more frequent screening to achieve more effective results.

In a study, researchers at Stanford University School of Medicine said that wearable sensors may provide a viable solution. Published online Thursday in PLOS Biology, the paper demonstrates that wearable sensors that monitor heart rate, activity, skin temperature, and other variables can reveal inflammation, insulin resistance, and the onset of infection, even when a patient otherwise doesn't notice anything wrong.

Collecting nearly 2 billion measurements from 60 people, the researchers gathered continuous data from wearable biosensor devices, and periodic data about blood chemistry, gene expression, and other parameters from laboratory tests.

Each person wore several monitors so that the group could collect more than 250,000 measurements per day. They collected information about weight; heart rate; blood oxygen levels; and skin temperature. They also kept track of activities such as sleep; walking; the number of steps taken; biking and running; and other data including calories expended; acceleration; and exposure to gamma rays and X-rays.

The researchers noted that elevated heart rate and blood pressure are associated with cardiovascular disease, and elevated body temperature occurs during pathogen infection and inflammation. Their study demonstrated that by using wearables it is possible to monitor deviations from normal measurements and link them with environmental conditions, illness, or other factors that affect health.

Distinctive patterns of deviation from normal seem to correlate with health problems, and algorithms designed to detect these patterns of change could potentially contribute to clinical diagnostics and research, they added.

In a statement from Stanford, Michael Snyder, professor and chair of genetics at the university, and a study subject for the paper, said that sensors he wore detected changes in his heart rate and blood oxygen levels during a long flight to Norway. While his oxygen levels normally dropped during flights and while his heart rate increased at the start of flights, they would usually return to normal levels during the flight and after he landed.

However, at the end of this flight, that didn't happen.

Two weeks earlier, Snyder had been in rural Massachusetts and was concerned that he may have been bitten by a tick and infected with Lyme disease. He convinced a doctor in Norway to prescribe him an antibiotic to treat the disease, and subsequent testing confirmed that Snyder had, indeed, been infected with Lyme disease.

“Wearables helped make the initial diagnosis,” Snyder said in the university's statement.

Wearable sensors with diagnostic applications are taking steps toward commercialization.

In December 2016, for example, New York-based Nanowear became one of the few companies developing wearable diagnostic monitoring devices to receive regulatory clearance from the US Food and Drug Administration. The firm received 510(k) clearance for its first product, the SimplECG medical-grade cardiac vest, which collects electrocardiogram, heart rate, and respiratory rate data from nanosensors embedded in the garment and transfers it to a web-based portal for review by a physician.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.

Sponsored by

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.